# US 2013/0251731 A1 · Tau Acetylation in the Pathogenesis of Alzheimers Disease and Other Related Tauopathies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2013/0251731 A1
- Document ID: US20130251731A1
- Status: Published application
- Kind: A1
- Application number: 13/799,842
- Filed: 2013-03-13
- Published: 2013-09-26
- Earliest claimed: 2012-03-22
- Assignees: The Trustees of the University of Pennsylvania
- Applicants: The Trustees of the University of Pennsylvania
- Inventors: Virginia M.Y. Lee; Todd J. Cohen; John Q. Trojanowski
- Web page: https://patentgrep.com/patent/US20130251731A1

## CPC

- C12Q 1/48: involving transferase
- G01N 33/6896: {Neurological disorders, e.g. Alzheimer's disease}
- G01N 2333/4709: Amyloid plaque core protein
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to biomarkers and diagnostic methods for Alzheimer's disease and other neurodegenerative disorders. The invention also provides compositions for detecting the biomarker as well as compositions and methods useful for treating Alzheimer's disease and other neurodegenerative disorders.

## Claims

### Claim 1

A method of diagnosing a neurodegenerative disorder in a subject, the method comprising determining the level of at least one biomarker in a biological sample obtained from the subject, wherein an elevated level of the biomarker in the sample compared to the level of the biomarker in a control sample is an indication of a neurodegenerative disorder, and further wherein the at least one biomarker comprises acetylated tau.

### Claim 2 (depends on 1)

The method of claim 1, wherein the neurodegenerative disorder is at least one disorder selected from the group consisting of Alzheimer's Disease (AD), corticobasal degeneration (CBD), Pick's disease (PiD), progressive supranuclear palsy, argyrophilic grain disease, tangle predominant senile dementia, Guam parkinsonism-dementia complex, frontotemporal dementia, frontotemporal lobar degeneration, FTDP-17, Lytico-Bodig disease, and Parkinson's disease.

### Claim 3 (depends on 1)

The method of claim 1, wherein acetylated tau is acetylated on at least one lysine residue selected from the group consisting of K150, K163, K174, K234, K240, K259, K274, K280, K281, K290, K311, K369, and K395.

### Claim 4 (depends on 1)

The method of claim 1, wherein the biomarker is detected by a method selected from the group consisting of immunohistochemistry, immunocytochemistry, immunofluorescence, immunoprecipitation, western blotting, and ELISA.

### Claim 5

A method of diagnosing a neurodegenerative disorder in a subject, the method comprising determining the level of at least one biomarker in a biological sample obtained from the subject, wherein the biomarker differentially discriminates between neurodegenerative disorders, and wherein the biomarker is acetylated tau.

### Claim 6 (depends on 5)

The method of claim 5, wherein the biomarker differentially discriminates between neurodegenerative disorders associated with 4R-tau and neurodegenerative disorders not associated with 4R-tau.

### Claim 7 (depends on 5)

The method of claim 5, wherein acetylated tau is acetylated on at least one lysine residue selected from the group consisting of K150, K163, K174, K234, K240, K259, K274, K280, K281, K290, K311, K369, and K395.

### Claim 8 (depends on 5)

The method of claim 5, wherein the biomarker is detected by at least one method selected from the group consisting of immunohistochemistry, immunofluorescence, western blotting, and ELISA.

### Claim 9

A composition that specifically recognizes a biomarker associated with a neurodegenerative disorder, wherein the biomarker is acetylated tau.

### Claim 10 (depends on 9)

The composition of claim 9, wherein acetylated tau is acetylated on at least one lysine residue selected from the group consisting of K150, K163, K174, K234, K240, K259, K274, K280, K281, K290, K311, K369, and K395.

### Claim 11 (depends on 9)

The composition of claim 9, wherein the neurodegenerative disorder Alzheimer's Disease (AD), corticobasal degeneration (CBD), Pick's disease (PiD), progressive supranuclear palsy, argyrophilic grain disease, tangle predominant senile dementia, Guam parkinsonism-dementia complex, frontotemporal dementia, frontotemporal lobar degeneration, FTDP-17, Lytico-Bodig disease, and Parkinson's disease.

### Claim 12 (depends on 9)

The composition of claim 9, wherein the composition comprises an antibody or fragment thereof.

### Claim 13

A composition for treating a neurodegenerative disorder in a subject, wherein the composition reduces the level of tau acetylation).

### Claim 14 (depends on 13)

The composition of claim 13, wherein the composition enhances the activity of at least one deacetylase.

### Claim 15 (depends on 13)

The composition of claim 13, wherein the composition reduces the activity of at least one acetyltransferase.

### Claim 16 (depends on 13)

The composition of claim 13, wherein the composition is selected from the group consisting of a peptide, a nucleic acid, an antibody, and a small molecule.

### Claim 17

A method of treating a neurodegenerative disorder in a subject, said method comprising administering to the subject an effective amount of a composition, wherein the composition reduces the level of tau acetylation.

### Claim 18 (depends on 17)

The method of claim 17, wherein the composition enhances the activity of at least one deacetylase.

### Claim 19 (depends on 17)

The method of claim 17, wherein the composition reduces the activity of at least one acetyl-transferase.

### Claim 20 (depends on 17)

The method of claim 17, wherein the composition is selected from the group consisting of a peptide, a nucleic acid, an antibody, and a small molecule.
